Fernandes Gabriela C, Michelli Rodrigo A D, Galvão Henrique C R, Paula André E, Pereira Rui, Andrade Carlos E, Felicio Paula S, Souza Cristiano P, Mendes Deise R P, Volc Sahlua, Berardinelli Gustavo N, Grasel Rebeca S, Sabato Cristina S, Viana Danilo V, Mauad Edmundo C, Scapulatempo-Neto Cristovam, Arun Banu, Reis Rui M, Palmero Edenir I
Center of Molecular Diagnosis, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Oncogenetics Department, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
Oncotarget. 2016 Dec 6;7(49):80465-80481. doi: 10.18632/oncotarget.12610.
There are very few data about the mutational profile of families at-risk for hereditary breast and ovarian cancer (HBOC) from Latin America (LA) and especially from Brazil, the largest and most populated country in LA.
Of the 349 probands analyzed, 21.5% were BRCA1/BRCA2 mutated, 65.3% at BRCA1 and 34.7% at BRCA2 gene. The mutation c.5266dupC (former 5382insC) was the most frequent alteration, representing 36.7% of the BRCA1 mutations and 24.0% of all mutations identified. Together with the BRCA1 c.3331_3334delCAAG mutation, these mutations constitutes about 35% of the identified mutations and more than 50% of the BRCA1 pathogenic mutations. Interestingly, six new mutations were identified. Additionally, 39 out of the 44 pathogenic mutations identified were not previously reported in the Brazilian population. Besides, 36 different variants of unknown significance (VUS) were identified. Regarding ancestry, average ancestry proportions were 70.6% European, 14.5% African, 8.0% Native American and 6.8% East Asian.
This study characterized 349 Brazilian families at-risk for HBOC regarding their germline BRCA1/BRCA2 status and genetic ancestry.
This is the largest report of BRCA1/BRCA2 assessment in an at-risk HBOC Brazilian population. We identified 21.5% of patients harboring BRCA1/BRCA2 mutations and characterized the genetic ancestry of a sample group at-risk for hereditary breast cancer showing once again how admixed is the Brazilian population. No association was found between genetic ancestry and mutational status. The knowledge of the mutational profile in a population can contribute to the definition of more cost-effective strategies for the identification of HBOC families.
关于拉丁美洲(LA),尤其是巴西(LA最大且人口最多的国家)遗传性乳腺癌和卵巢癌(HBOC)高危家族的突变谱数据非常少。
在分析的349名先证者中,21.5%存在BRCA1/BRCA2突变,其中BRCA1基因突变为65.3%,BRCA2基因突变为34.7%。突变c.5266dupC(原5382insC)是最常见的改变,占BRCA1突变的36.7%,占所有已鉴定突变的24.0%。这些突变与BRCA1 c.3331_3334delCAAG突变一起,构成了约35%的已鉴定突变和超过50%的BRCA1致病突变。有趣的是,还鉴定出了6个新突变。此外,在鉴定出的44个致病突变中,有39个此前未在巴西人群中报道过。此外,还鉴定出36种意义未明的不同变异(VUS)。关于血统,平均血统比例为欧洲人70.6%、非洲人14.5%、美洲原住民8.0%和东亚人6.8%。
本研究对349个巴西HBOC高危家族的种系BRCA1/BRCA2状态和遗传血统进行了特征分析。
这是关于巴西HBOC高危人群中BRCA1/BRCA2评估的最大规模报告。我们发现21.5%的患者携带BRCA1/BRCA2突变,并对一组遗传性乳腺癌高危样本群体的遗传血统进行了特征分析,再次表明巴西人群的混杂程度。未发现遗传血统与突变状态之间存在关联。了解人群中的突变谱有助于确定更具成本效益的HBOC家族识别策略。